

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number  
**WO 2004/087124 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/155**,  
C07C 257/12, A61P 25/18

(21) International Application Number:  
PCT/GB2004/001367

(22) International Filing Date: 29 March 2004 (29.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0307370.7 29 March 2003 (29.03.2003) GB  
0307366.5 29 March 2003 (29.03.2003) GB

(71) Applicant (for all designated States except US): **MIT-SUBISHI PHARMA CORPORATION** [JP/JP]; 2-2-6 Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8405 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIZOS, Dimitrios, Evangelou** [GR/GB]; Yoshitomi Institute of Neuroscience in Glasgow (YR, ING), West Medical Building, University of Glasgow, Glasgow G12 8QQ (GB). **McKERCHAR, Clare** [GB/GB]; Yoshitomi Institute of Neuroscience in Glasgow (YR, ING), West Medical Building, University of Glasgow, Glasgow G12 8QQ (GB). **MURPHY, John** [GB/GB]; University of Strathclyde, Department of Pure & Applied Chemistry, McCance Building, 295 Cathedral Street, Glasgow G1 1XL (GB). **SHIIGI, Yasuyuki** [JP/JP]; Mitsubishi Pharma Corporation, 2-6 Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **SUCKLING, Colin** [GB/GB]; University of Strathclyde, Department of Pure and Applied Chemistry, McCance Building, 295 Cathedral Street, Glasgow G1 1XL (GB). **YASUMATSU, Hiroshi** [JP/JP]; Mitsubishi Pharma Corporation, 2-6 Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **ZHOU, Sheng-ze** [CN/JP]; Mitsubishi Pharma

Corporation, 2-6 Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **PRATT, Judith** [GB/GB]; Yoshitomi Institute of Neuroscience in Glasgow (YRING), West Medical Building, University of Glasgow, Glasgow G12 8QQ (GB). **MORRIS, Brian** [GB/GB]; Yoshitomi Institute of Neuroscience in Glasgow (YR, ING), West Medical Building, University of Glasgow, Glasgow G12 8QQ (GB).

(74) Agents: **MACDOUGALL, Donald, Carmichael et al.**; Marks & Clerk, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS HAVING SEROTONIN 5-HT<sub>17</sub> RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M<sub>4</sub> RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS

(57) Abstract: The present invention relates to novel treatments for schizophrenia, based on the concept of identifying agents capable of selectively binding to the serotonin 5-HT<sub>7</sub> and muscarinic M<sub>4</sub> receptors and the use of such compounds in treating schizophrenia. The present invention also relates to novel amidine compounds for treating schizophrenia, a method of manufacturing such compounds, pharmaceutical formulations comprising said compounds, as well as medical uses and methods of treatment using said compounds.



WO 2004/087124 A1